TA1 vs Thymulin
A side-by-side research comparison of TA1 and Thymulin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | TA1 | Thymulin |
|---|---|---|
| Full name | Thymosin Alpha-1 (TA1 - Clinical Form) | Thymulin (Facteur Thymique Serique) |
| Category | Immune Support | Immune Support |
| Status | Approved internationally (not FDA-approved) | Research compound |
| Mechanism | Activates TLR2/9 on dendritic cells, promotes T-cell differentiation, and enhances cytokine-mediated immune signaling cascades. | Binds to specific receptors on T-cell precursors promoting their differentiation into mature T-cells, modulates cytokine production, and requires zinc as cofactor. |
| Molecular weight | 3108.3 Da | 847.9 Da |
| Half-life | ~2-3 hours | ~2 hours |
| Bioavailability | ~85% subcutaneous | ~80% subcutaneous |
| Typical dose | 1.6 mg | 1-5 mg |
| Frequency | 2x per week | 2-3x per week |
| Route | Subcutaneous injection | Subcutaneous injection |
TA1 reported benefits
- Standardized immune enhancement
- Proven antiviral adjunct
- Cancer immunotherapy support
- Vaccine response enhancement
Thymulin reported benefits
- T-cell maturation support
- Thymic function restoration
- Zinc-dependent immune activation
- Anti-inflammatory properties
Related comparisons
Research and educational reference only. Not medical advice.